Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Treatments compared for pediatric-onset multiple sclerosis

Summary by Ground News
More patients with POMS are free of new or newly enlarging lesions with dimethyl fumarate. The annualized relapse rate is lower with DMF, according to a study in JAMA. Suicide risk is highest in the first three months after the dementia diagnosis.

2 Articles

HealthDayHealthDay
Center

Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate

Read Full Article
Medical XpressMedical Xpress
Center

Treatments compared for pediatric-onset multiple sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news on Thursday, October 6, 2022.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Multiple Sclerosis icon

Multiple Sclerosis

Medical icon

Medical

Billings, Montana icon

Billings, Montana

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal